Cadila Healthcare slips after Q3 PAT declines 5% YoY to Rs 500 cr

3 Feb 2022 , 02:32 PM

On a consolidated basis, profit before tax rose 1.46% to Rs 599 crore in Q3 December 2021 over Q3 December 2020.

Earnings before Interest, Depreciation and Tax (EBIDTA) stood at Rs 753 crore, down 1.83% YoY and down 12.54% QoQ.

India formulations business posted revenues of Rs 1079 crore during the quarter. The branded formulations business posted a robust double-digit growth of 17% on a y-o-y basis.

US formulations business registered revenues of Rs 1504 crore during the quarter. The company filed 12 additional ANDAs with the USFDA during the quarter and received 9 new product approvals (including 5 tentative approvals) from the USFDA. The company launched 3 new products in the US market including Nelarabine injection which was granted 180 days exclusivity and was a day 1 launch. It is a chemotherapy drug used to treat certain types of leukemia and lymphoma.

Cadila Healthcare is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

Powered by Capital Market – Live News